Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Prognostic Significance of Re-Induction Necessity Based on Day-14 Residual Disease and Age-Adjusted Consolidation Approaches in Acute Myeloid Leukemia

  • By

  • Abiola Bolarinwa

  • Muhammad Yousuf

  • Aref Al-Kali

  • Hassan B. Alkhateeb

  • Abhishek A. Mangaonkar

  • Antoine N. Saliba

  • Mehrdad Hefazi Torghabeh

  • Aasiya Matin

  • Michelle A. Elliott

  • Mark R. Litzow

  • William J. Hogan

  • Mithun V. Shah

  • Mrinal M. Patnaik

  • Animesh Pardanani

  • Dong Chen

  • Kaaren K. Reichard

  • Rong He

  • Naseema Gangat

  • Ayalew Tefferi

  • Kebede H. Begna

  • September 30, 2026

Share

  • 1

    Induction treatment for AML aims for complete remission, with re-induction recommended if residual disease exceeds 5% blasts on day 14.

  • 2

    The study evaluated 279 AML patients, finding that re-induction was necessary for 27% due to residual disease or persistent extramedullary disease.

  • 3

    Multivariable analysis indicated that age ≥65 years, post-CMN status, adverse karyotype, and re-induction requirement independently predicted relapse.

  • 4

    Overall survival was significantly lower for patients requiring re-induction, with median OS of 37 months compared to 106 months for those who did not.

  • 5

    Consolidation regimens showed varied outcomes, with IDAC yielding longer RFS and OS in older patients compared to anthracycline-based regimens.

Original Source(s)

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

  • by Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A. Elliott, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Dong Chen, Kaaren K. Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H. Begna

  • September 30, 2026

Related Content

Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

  • October 15, 2026

  • 1 min